At a glance
Below is a list of recent scientific articles generated from CDC programs and activities.
Articles about SCD
2024
Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications.
Singh A, Brousseau DC, Dasgupta M, Shet AS, Field JJ, Brandow AM. PLoS One. 2024 Apr 16;19(4):e0297469. doi: 10.1371/journal.pone.0297469. PMID: 38626063; PMCID: PMC11020686.
Assessing patterns of telehealth use among people with sickle cell disease enrolled in Medicaid during the start of the COVID-19 pandemic.
Reeves SL, Plegue M, Patel PN, Paulukonis ST, Horiuchi SS, Zhou M, Attell BK, Pace BS, Snyder AB, Plaxco AP, Mukhopadhyay A, Smeltzer MP, Ellimootil CS, Hulihan M. Telemed J E Health. 2024 Apr 11. doi: 10.1089/tmj.2023.0422. Epub ahead of print. PMID: 38603584.
Birth Prevalence of Sickle Cell Disease and County-Level Social Vulnerability — Sickle Cell Data Collection Program, 11 States, 2016–2020.
Kayle M, Blewer AL, Pan W, et al. MMWR Morb Mortal Wkly Rep 2024;73:248–254. DOI: http://dx.doi.org/10.15585/mmwr.mm7312a1.
COVID-19 immunization coverage among people with sickle cell disease.
Peng HK, Dombkowski KJ, Plegue MA, Latta K, Malosh R, Creary MS, Reeves SL. JAMA Netw Open. 2024 Jan 2;7(1):e2351618. doi: 10.1001/jamanetworkopen.2023.51618.
2023
Evaluating the discriminatory ability of the Sickle Cell Data Collection program's administrative claims case definition in identifying adults with sickle cell disease: validation study.
Singh A, Sontag MK, Zhou M, Dasgupta M, Crume T, McLemore M, Galadanci N, Randall E, Steiner N, Brandow AM, Koch K, Field JJ, Hassell K, Snyder AB, Kanter J. JMIR Public Health Surveill. 2023 Jun 28;9:e42816. doi: 10.2196/42816.
Common data model for sickle cell disease surveillance: considerations and implications.
Smeltzer MP, Reeves SL, Cooper WO, Attell BK, Strouse JJ, Takemoto CM, Kanter J, Latta K, Plaxco AP, Davis RL, Hatch D, Reyes C, Dombkowski K, Snyder A, Paulukonis S, Singh A, Kayle M. JAMIA Open. 2023 May 27;6(2):ooad036. doi: 10.1093/jamiaopen/ooad036.
Increasing visibility of sickle cell disease in Indiana: establishing baseline prevalence using integrated data from multiple sources.
Okolo AI, Jacob SA, Dixon BE, Valvi NR, Janson IA, Hardesty BM. Public Health Rep. 2023 May 26:333549231170229. doi: 10.1177/00333549231170229.
Case ascertainment of sickle cell disease using surveillance or single administrative database case definitions.
Reeves SL, Horiuchi S, Zhou M, Paulukonis S, Snyder A, Wilson-Frederick S, Hulihan M. Public Health Rep. 2023 May 19:333549231166465. doi: 10.1177/00333549231166465.
COVID-19 infection and outcomes in newborn screening cohorts of sickle cell trait and sickle cell disease in Michigan and Georgia.
Paulukonis ST, Snyder A, Smeltzer MP, Sutaria AN, Hurden I, Latta K, Chennuri S, Vichinsky E, Reeves SL. J Pediatr Hematol Oncol. 2023 May 1;45(4):174-180. doi: 10.1097/MPH.000000000000267.
Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004–2019.
Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB. Pediatr Blood Cancer. 2023 Mar;70(3):e30152. doi: 10.1002/pbc.30152.
2022
Use of recommended health care measures to prevent selected complications of sickle cell anemia in children and adolescents — Selected U.S. states, 2019.
Schieve LA, Simmons GM, Payne AB, et al. MMWR Morb Mortal Wkly Rep 2022;71:1241–1246. doi: http://dx.doi.org/10.15585/mmwr.mm7139e1.
Prioritizing sickle cell disease.
Lewis L. Hsu, W. Craig Hooper, Laura A. Schieve. Pediatrics December 2022; 150 (6): e2022059491. 10.1542/peds.2022-059491
Sickle cell disease among Latinx in California.
Valle J, Baker JR, Madrigal D, Ferrerosa J, Paulukonis S. PLoS One. 2022 Oct 27;17(10):e0276653. doi: 10.1371/journal.pone.0276653.
Surveillance for the rare condition of sickle cell disease in Wisconsin. Singh A, Dasgupta M, Retherford D, Baker M, Hulihan M, Brandow AM. WMJ. 2022 Dec;121(4):297-300.
Surveillance for sickle cell disease — Sickle Cell Data Collection program, two states, 2004–2018.
Snyder AB, Lakshmanan S, Hulihan MM, et al. MMWR Surveill Summ 2022;71(No. SS-9):1–18. doi: http://dx.doi.org/10.15585/mmwr.ss7109a1.
COVID-19 and sickle cell disease-related deaths reported in the United States.
Payne AB, Schieve LA, Abe K, Hulihan M, Hooper WC, Hsu LL. Public Health Rep. 2022 Mar-Apr;137(2):234-238. doi: 10.1177/00333549211063518.
Hematologist encounters among Medicaid patients who have sickle cell disease.
Horiuchi SS, Zhou M, Snyder A, Paulukonis ST. Blood Adv. 2022 Sep 13;6(17):5128-5131. doi: 10.1182/bloodadvances.2022007622.
2021
Influenza vaccination rates and hospitalizations among Medicaid enrollees with and without sickle cell disease, 2009-2015.
Payne AB, Adamkiewicz TV, Grosse SD, Steffens A, Shay DK, Reed C, Schieve LA. Pediatr Blood Cancer. 2021 Dec;68(12):e29351. doi: 10.1002/pbc.29351.
Improving outcomes for patients with sickle cell disease in the United States: making the case for more resources, surveillance, and longitudinal data.
Kanter J, Meier ER, Hankins JS, Paulukonis ST, Snyder AB. JAMA Health Forum. 2021 Oct 1;2(10):e213467. doi: 10.1001/jamahealthforum.2021.3467.
Hydroxyurea use after transitions of care among young adults with sickle cell disease and Tennessee Medicaid insurance.
Mathias JG, Nolan VG, Klesges LM, Badawy SM, Cooper WO, Hankins JS, Smeltzer MP. JAMA Netw Open. 2021 Oct 1;4(10):e2128971. doi: 10.1001/jamanetworkopen.2021.28971.
Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease.
Wong TE, Valle J, Paulukonis S. Health Sci Rep. 2021 Jul 14;4(3):e323. doi: 10.1002/hsr2.323.
2020
Coronavirus disease among persons with sickle cell disease, United States, March 20–May 21, 2020.
Panepinto JA, Brandow A, Mucalo L, Yusuf F, Singh A, Taylor B, Payne AB, Peacock G, Schieve LA. Emerging Infectious Diseases. 2020 Oct. doi: 10.3201/eid2610.202792.
Trends in sickle cell disease-related mortality in the United States, 1979–2017.
Payne AB, Mehal JM, Chapman C, Haberling DL, Richardson LC, Bean CJ, Hooper WC. Annals of Emergency Medicine. 2020; 76 (3S):S28-S36
Using surveillance to determine the number of individuals with sickle cell disease in California and Georgia, 2005-2016.
Aluc A, Zhou M, Paulukonis ST, Snyder AB, Wong D, Hulihan MM. [published online ahead of print, 2020 Aug 12]. Pediatr Hematol Oncol. 2020;1-5. doi:10.1080/08880018.2020.1779886
Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M, Valle J, Paulukonis S, Holl JL, Tanabe P, French DD, Garg R, Liem RI, Badawy SM, Treadwell MJ. Pediatr Blood Cancer. 2020 May;67(5):e28152.
Acute care utilization at end of life in sickle cell disease: Highlighting the need for a palliative approach.
Johnston EE, Adesina OO, Alvarez E, Amato H, Paulukonis S, Nichols A, Chamberlain LJ, Bhatia S. J Palliat Med. 2020 Jan;23(1):24-32.
2019
Characterizing complication risk from multisite, intermittent transfusions for the treatment of sickle cell disease.
Tang A, Branscomb J, Zhou M, Snyder A, Eckman J. Pediatr Blood Cancer. 2019 Oct;66(10):e27921.
Health literacy and knowledge of chronic transfusion therapy in adolescents with sickle cell disease and caregivers.
Yee MEM, Meyer EK, Fasano, RM, Lane PA, Josephson CD, Brega AG. Pediatr Blood Cancer. 2019 Jul;66(7):e27733.
Understanding the complications of sickle cell disease.
Tanabe P, Spratling R, Smith D, Grissom P, Hulihan M. American Journal of Nursing 2019 June; 119 (6) 26-35. doi: 10.1097/01.NAJ.0000559779.40570.2c
Improving an administrative case definition for longitudinal surveillance of sickle cell disease
Snyder AB,Zhou M, Theodore R, Quarmyne MO, Eckman J, Lane PA. Public Health Rep. 2019 May/Jun;134(3):274-281. doi: 10.1177/0033354919839072.
Transfusion service knowledge and immunohaematological practices related to sickle cell disease and thalassemia.
Fasano RM, Branscomb J, Lane PA, Josephson CD, Snyder AB, Eckman JR. Transfus Med. 2019 Feb 10.
Facilitators and barriers to minority blood donations: A systematic review.
Spratling R, Lawrence RH. Nurs Res. 2019 Mar 1. [Epub ahead of print].
2018
A strategic planning tool for increasing African American blood donation.
Singleton A, Spratling R. Health Promot Pract. 2018 May 1:1524839918775733. doi: 10.1177/1524839918775733.
Hemoglobin A clearance in children with sickle cell anemia on chronic transfusion therapy.
Yee MEM, Josephson CD, Winkler AM, Webb J, Luban NLC, Leong T, Stowell SR, Roback JD, Fasano RM. Transfusion. 2018 Apr 17. doi: 10.1111/trf.14610.
2017
CDC Grand Rounds: Improving the lives of persons with sickle cell disease.
Hulihan M, Hassell KL, Raphael JL, Smith-Whitley K, Thorpe P. MMWR Morb Mortal Wkly Rep. 2017 Nov 24;66(46):1269-1271. doi: 10.15585/mmwr.mm6646a2.
Emergency department utilization by Californians with sickle cell disease, 2005-2014.
Paulukonis ST, Feuchtbaum LB, Coates TD, Neumayr LD, Treadwell MJ, Vichinsky EP, Hulihan MM. Pediatr Blood Cancer. 2017 Jun;64(6):10.1002/pbc.26390. doi: 10.1002/pbc.26390.
Red blood cell minor antigen mismatches during chronic transfusion therapy for sickle cell anemia.
Yee MEM, Josephson CD, Winkler AM, Webb J, Luban NLC, Leong T, Stowell SR, Fasano RM. Transfusion. 2017 Nov;57(11):2738-2746. doi: 10.1111/trf.14282.
The accuracy of hospital ICD-9-CM codes for determining sickle cell disease genotype.
Snyder AB, Lane PA, Zhou M, Paulukonis ST, Hulihan MM. J Rare Dis Res Treat. 2017;2(4):39-45.